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She year 2008 was extraordinary because of the number of
eports from major clinical outcome trials of blood pressure
BP)-lowering therapies. Consequently, this review of the
ast year in hypertension will primarily focus on these
linical trials and their likely impact on future treatment
uidelines. However, there were also important reports on
he global burden of hypertension, recommendations for
ome BP measurement, impact of nutritional factors on the
ncidence of hypertension, resistant hypertension, and treat-
ent strategies for improving BP control in general.
he Global Burden of
P-Related Morbidity and Mortality
he burden of cardiovascular disease and mortality attrib-
table to an elevated BP was estimated from the Global
urden of Disease 2000 study, recently updated to include
ore recent country-level data (1). The population burden
f disease attributable to an elevated BP was estimated as
he proportional reduction in average disease risk that would
esult from elimination of an elevated systolic BP (systolic
P 115 mm Hg), assuming the distributions of other risk
actors remain unchanged over a defined time period.
In 2001,7.6 million deaths worldwide were attributable
o an elevated systolic BP, 14% of all deaths (1). Approx-
mately 54% of all strokes and 47% of all ischemic heart
isease was attributable to high BP. The majority (80%)
f this BP-attributable disease burden occurred in low- and
iddle-income countries, with more than one-half occur-
ing among people of working age (45 to 69 years). This
nding suggests that since these data were generated in
000, 60 million people have died worldwide as a conse-
uence of high BP. It is interesting to reflect on this clear
nd present danger and the minimal worldwide attention
ocused on it, alongside the recent global panic regarding
nfluenza. How many people wearing paper masks actually
now what their BP is?
Another interesting aspect of the report is that approxi-
ately one-half of the BP-attributable deaths are due to
ystolic BP levels between the optimal systolic BP level
defined in the report as 115 mm Hg) and the current
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Manuscript received July 13, 2009; accepted August 25, 2009.herapeutic intervention threshold in guidelines of 140/90
m Hg (1). Thus, a major component of the population
urden of BP-attributable disease occurs at BP levels that
ay be considered suboptimal (namely, systolic BP of 115
o 140 mm Hg) but for which we have no evidence of the
enefit versus harm of further BP lowering. That presents
oth a clinical and a socioeconomic challenge: 1) can we
enerate the evidence for treatment benefit for people in this
ategory; and 2) would populations accept and could they
fford treatment of what would be the majority of the adult
opulation?
ome Blood Pressure Measurement (HBPM)
recent “call to action” statement from the American Heart
ssociation has recommended wider use of HBPM to
vercome “many of the limitations of traditional office BP
easurement,” adding that it is “both cheaper and easier to
erform than ambulatory BP monitoring” (2). This report
ecommended that HBPM should become a routine com-
onent of BP measurement for the majority of patients with
nown or suspected hypertension using validated oscillo-
etric monitors that measure BP on the upper arm with an
ppropriate cuff size. It went on to recommend that 2 to 3
eadings should be taken while the subject is resting in the
eated position, both in the morning and the evening, over
period of 1 week. An average total of 12 readings is
ecommended for making clinical decisions. This method is
idely used in Europe, and guidelines from Europe for
BPM were discussed in last year’s review of the year in
ypertension (3). Evidence is accruing to suggest that
BPM may be a better predictor of target organ damage
nd also helps reduce the “white coat effect” and determine
he presence of “masked hypertension.” The levels of aver-
ge HBPM considered normal by the majority of the
uidelines are 135 mm Hg for average systolic BP and
85 mm Hg for average diastolic BP (see Pickering et al.
2] for references). The Japanese guidelines regard “definite
ormotension” as an average pressure of 125/75 mm Hg
nd “definite hypertension” as 135/85 mm Hg, and the
ritish Hypertension Society stated that average home BP
evels of 130/85 mm Hg can “probably be regarded as
ormal.” The World Health Organization–International
ociety of Hypertension Guidelines recommended an upper
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ardiology (ESH/ESC) guidelines suggested that the def-
nition of hypertension for HBPM was 130 to 135 mm
g for systolic BP and 85 mm Hg for diastolic BP. Thus,
here are similarities in these thresholds but no international
onsensus as yet. Most patients are suitable for HBPM but
o need instruction in the methods. Those unsuitable
nclude patients with atrial fibrillation or other significant
ardiac rhythm disturbances that make automated oscillo-
etric devices unreliable.
utritional Aspects:
airy Products and Incident Hypertension
here has been much interest in the relationship between
airy product consumption and incident hypertension. A
revious cross-sectional study from Framingham has sug-
ested that children who consumed 2 or more servings of
airy products per day during their preschool years had a
maller rise in systolic BP throughout their childhood years
nd a lower systolic BP during adolescence (4). Other
tudies have also suggested an inverse relationship between
airy product consumption and metabolic syndrome, inci-
ent type 2 diabetes mellitus, and cardiovascular disease
5–7). A recent large prospective cohort study of middle-
ged and older women also demonstrated an inverse asso-
iation between low-fat dairy product intake and the risk of
ncident hypertension (8). The association was moderate,
raded, and independent of known risk factors for hyper-
ension. Of interest, there was no such relationship if the
airy intake was high fat, suggesting that the fat content of
airy intake influences the strength of the relationship.
Vitamin D levels influence calcium uptake, and there was
lso an inverse relationship between the calcium and vitamin
content of the diet and incident hypertension (8).
oreover, the association between low-fat dairy intake and
ncident hypertension was substantially attenuated after
djustment for the dietary calcium content, pointing to the
mportance of calcium intake in the relationship between
ow-fat dairy product consumption and incident hyperten-
ion. Of interest, there was no such relationship if the
alcium and vitamin D were provided as supplements. It is
nclear why high-fat dairy intake attenuates the aforemen-
ioned relationships, but it is conceivable that high saturated
at content offsets the cardiovascular benefits and/or im-
edes intestinal calcium absorption. These findings point to
he potential importance of low-fat dairy product intake in
he primary prevention of hypertension and cardiovascular
isease and lend support to the 2005 dietary guideline from
he U.S. Department of Agriculture, which recommended
hat the majority of Americans increase their intake of dairy
roducts to 3 portions per day. These new data suggest that
his recommendation should be qualified by emphasizing
hat the dairy products should be low fat. If implemented,
uch recommendations could have substantial public health
mplications. cecent BP-Lowering Trials and
heir Implications for Clinical Practice
n 2008, the results of 5 major clinical outcomes trials
esting BP-lowering drugs were reported. These studies
ddressed some fundamental questions and succeeded in
roviding key information that will no doubt help frame
uture treatment guidelines—medical politics notwithstand-
ng. These trials and their implications are reviewed below.
he ONTARGET (Ongoing Telmisartan Alone and in
ombination With Ramipril Global Endpoint Trial)
rogram. The ONTARGET program (9) addressed 2 im-
ortant questions: 1) Is telmisartan, an angiotensin-receptor
locker (ARB) noninferior to ramipril, an angiotensin-
onverting enzyme (ACE) inhibitor, at preventing a com-
osite of cardiovascular events in a population of patients at
igh risk for cardiovascular disease? 2) Is the combination of
amipril and telmisartan more effective than ramipril alone
t preventing cardiovascular events? The demographics of
he study population of 25,620 patients were similar to
hose of the HOPE (Heart Outcomes Prevention Evalua-
ion) trial (10), which established that the ACE inhibitor
amipril reduced cardiovascular morbidity and mortality,
amely, the patients had evidence of vascular disease or
igh-risk diabetes mellitus without heart failure at baseline.
he mean age of ONTARGET participants was 66.5
ears, 63% were male, 85% had cardiovascular disease, 69%
ere hypertensive, and 38% were diabetic. However, when
ompared with the HOPE trial, many more patients in the
NTARGET study were receiving proven cardiovascular
isk-reducing therapies at baseline, including statins (62%),
ntiplatelet therapy (82%), beta-blockers (57%), and diuret-
cs (28%). The primary outcome of the ONTARGET study
as similar to that of the HOPE trial, namely, a composite
f death from cardiovascular causes, myocardial infarction,
r stroke, but also included hospitalization for heart failure.
he median follow-up of the study was 56 months. An
nteresting feature of the design was a 3-week run-in period
uring which patients were exposed to low-dose ramipril
nd then ramipril plus telmisartan to establish tolerability of
he treatment regimen before randomization. Of those who
ere randomly allocated to the run-in, 12% withdrew. The
ean BP at randomization was 148/82 mm Hg, and the fall
n BP during the trial was 6.0/4.6 mm Hg with ramipril,
6.9/5.2 mm Hg with telmisartan, and 8.4/6.0 mm Hg
ith the combination—the differences were small but sta-
istically significant.
The comparison of telmisartan 80 mg daily versus
amipril 10 mg daily showed that telmisartan was noninfe-
ior to ramipril with regard to the primary end point, and
his was consistent for all components of the primary
utcome (9). This conclusion was unchanged after adjust-
ent for the small differences in BP. Turning to the
omparison of the combination of telmisartan with ramipril,
ersus ramipril alone, it was a surprise to many that the













































































































67JACC Vol. 55, No. 1, 2010 Williams
December 29, 2009/January 5, 2010:65–73 Year in Hypertensionutcome, mindful of the fact that BP was lower with the
ombination. Moreover, there were significantly more with-
rawals from combination therapy and more adverse events,
specially the onset of renal impairment.
The ONTARGET trial suggests that the ARB was likely
o be equivalent to the ACE inhibitor at preventing cardio-
ascular events in this high-risk population and was better
olerated, with less withdrawal from therapy. The better
olerability of ARBs was most likely underestimated by the
NTARGET trial because drug exposure during the
un-in excluded patients (12%) who failed to tolerate lower
oses of the trial medications. The finding of noninferiority
f the ARB challenges the controversial conclusions gener-
ted by some previous meta-analyses that ARBs may be less
ffective at preventing myocardial infarction than ACE
nhibitors are. The findings of the ONTARGET study
rovide doctors with reassurance that when this controver-
ial hypothesis was formally tested in a major randomized
linical trial, there was no signal of inferiority with the ARB
n preventing myocardial infarction. Thus, in general, an
RB can be considered a better tolerated, equivalent, and
uitable alternative to an ACE inhibitor.
One of the surprises of the ONTARGET study was that
he differential BP lowering between treatments and the
onger duration of action of ARBs versus ACE inhibition,
id not translate into a better outcome, especially for stroke.
here are a number of considerations with regard to these
ndings. First, the reported data show only average BP
hanges, and it is conceivable that patients with higher
aseline pressures achieved some benefit with greater BP
owering and patients with lower baseline BP achieved no
enefit, or harm. Thus, the net effect was neutral. This
ypothesis has been subsequently evaluated by examination
f outcomes stratified according to baseline BP and the
n-trial BP change (11). Second, another consideration is
hat the baseline BP was not especially high and many
atients were receiving concomitant BP-lowering medica-
ions. Previous studies have shown that telmisartan is
ignificantly more effective than ramipril at lowering BP
ver 24 h (12), and it is conceivable that had the study been
onducted among patients who were overtly hypertensive,
his BP-lowering advantage of telmisartan may have trans-
ated into a greater differences in BP throughout the trial,
nd a potentially a different outcome. In this regard, analysis
f the 24-h BP data from an ONTARGET substudy will be
f interest. Third, this study also generates uncertainty
bout the benefits of aggressive BP lowering in this popu-
ation of patients and underscores the need for further trials
xploring the safety and efficacy of BP lowering in patients
t high cardiovascular disease risk in whom BP is not overtly
levated at baseline.
The data from the ONTARGET study with regard to
he lack of benefit and potential harm of an ACE inhibitor/
RB combination has had a more telling impact. It has
ffectively shelved the launch of such combinations by
harmaceutical companies and suggests that doctors should oot be using this combination in routine clinical practice.
here are some circumstances where the use of an ACE
nhibitor/ARB combination will still be used, such as for
atients with severe heart failure or patients with advanced
hronic renal disease and heavy proteinuria, but this requires
areful consideration of the balance between benefit and
arm, as is discussed in the following text in relation to renal
isease. This finding from the ONTARGET study also
aises intriguing questions about whether other strategies to
eliver dual blockade of the renin-angiotensin system,
amely, ACE inhibition or ARB plus a direct renin inhib-
tor, will be more effective. Such important questions are
eing addressed by the ongoing clinical trial program with
liskiren, a direct renin inhibitor that is being added to
xisting therapy for patients already being treated with an
CE inhibitor or ARB who have heart failure or diabetic
ephropathy.
ual renin-angiotensin system (RAS) blockade and renal
isease: on or off target? A pre-specified secondary anal-
sis of the ONTARGET trial examined the impact of
amipril and telmisartan and the combination on regression
f proteinuria and a primary composite outcome of dialysis,
oubling of serum creatinine, and death (13). The number
f events for the composite primary outcome was similar for
elmisartan (n  1,147 [13.4%]) and ramipril (n  1,150
13.5%]) but was significantly increased with combination
herapy (n  1,233 [14.5%]). The urinary albumin/
reatinine ratio increased in all groups during the trial, but
east with the combination. Moreover, the risk of develop-
ng new microalbuminuria was similar with ramipril or
elmisartan but was significantly less with the combination.
hus, there appeared to be dissociation between the effects of
he treatments on albuminuria and risk of developing the
rimary composite outcome. This was a red rag to the
ephrological bull, challenging the holy grail of nephrology,
hich has long associated more effective reduction of albumin-
ria with nephroprotection. There are, however, a number of
mportant caveats to consider with regard to this renal outcome
ata before jumping to simplistic conclusions. 1) The primary
omposite end point examined in the ONTARGET study
enal outcomes report was dominated, and primarily driven, by
eath. The number of patients progressing to chronic dialysis,
r experiencing a doubling of serum creatinine, was not
ignificantly different between groups. This is an important
essage in itself, highlighting that patients at high cardio-
ascular disease risk and/or with diabetes, whether or not
hey had significant albuminuria or renal impairment, were
uch more likely to die than reach a conventional renal end
oint. 2) The percentage of patients in the ONTARGET
tudy with significant renal impairment at baseline was low,
nd the scrutiny of renal disease progression was not as
igorous as would normally be employed in a dedicated renal
utcomes study—moreover, only 98 of 25,000 patients
rogressed to chronic dialysis. Thus, the finding from the
NTARGET renal substudy should not undermine previ-
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Year in Hypertension December 29, 2009/January 5, 2010:65–73ance of RAS blockade in delaying the progression of more
dvanced chronic renal disease (namely, in patients with an
stimated glomerular filtration rate 60 ml/min and overt
roteinuria 300 mg/day) due to diabetic and nondiabetic
ephropathy. 3) It is also possible that patients who expe-
ienced renal end points such as dialysis with the combina-
ion therapy did so because more aggressive RAS blockade
redisposed them to more acute renal failure due to acute
isturbances to volume homeostasis, rather than accelerated
rogression of chronic renal impairment. Review of the data
upports this conclusion—the significant difference in re-
uirement for dialysis between treatment groups reflected
ore acute dialysis, rather than chronic dialysis, of patients
reated with the combination.
In summary, the renal data from the ONTARGET study
uggest that an ACE inhibitor/ARB combination has no
dvantages and should not be routinely used for patients
ith chronic renal disease and low-grade albuminuria and a
ow risk of developing end-stage renal disease. For such
atients, treatment with optimal doses of an ACE inhibitor
r ARB as part of their BP-lowering treatment regimen
ould be more appropriate. As for patients with advanced
hronic renal disease and more significant proteinuria,
urther studies are required to better define the place in
reatment for an ACE inhibitor/ARB combination or other
ombinations designed to further enhance the inhibition of
he RAS—the data from the ONTARGET study does not
reclude such studies; indeed, it mandates them.
Turning to other combinations to deliver dual blockade
f the RAS with regard to nephroprotection, Parving et al.
14) recently reported the results of the AVOID (Aliskiren
n the eValuation of prOteinuria In Diabetes) study, which
tudied 599 patients with diabetic nephropathy and protein-
ria. The patients had a baseline estimated glomerular
ltration rate of 68 ml/min/1.73 m2 and a baseline
lbumin/creatinine ratio of 500, indicative of proteinuria.
hey were all treated with a maximum recommended dose
f losartan 100 mg daily in addition to other BP-lowering
edication, which achieved an average baseline BP of
135/78 mm Hg. The patients were then randomly as-
igned to the addition of aliskiren 300 mg daily, a direct
enin inhibitor, or placebo, in addition to their existing
edication. That resulted in a comparison of dual RAS
lockade, namely, direct renin inhibitor plus ARB versus an
RB plus placebo. The primary outcome was the reduction
n the albumin/creatinine ratio in an early morning urine
ample, 6 months after randomization. The addition of
liskiren-based treatment significantly reduced the mean
rinary albumin/creatinine ratio by 20%. Moreover, when
omparing treatment groups, there were minimal differences
n BP (2/1 mmHg in favor of aliskiren) and no significant
ifferences in adverse event rates. Careful monitoring of
otassium levels will be required in patients with renal
mpairment who receive dual RAS blockade, but the inci-
ence of significant hyperkalemia (6 mmol/l) was surpris-
ngly low (aliskiren plus ARB, 4.7%; placebo plus ARB, r.7%) and was often transient, leading to study withdrawal
f very few patients (14). These results are promising, and
t will be of interest to see whether an ongoing clinical
utcomes study of patients with diabetic nephropathy
onfirms the superiority of dual RAS blockade with an
RB and aliskiren versus ARB-based therapy alone (15).
he TRANSCEND (Telmisartan Randomised Assess-
ent Study in ACE Intolerant Subjects With Cardio-
ascular Disease) study. The TRANSCEND study was
omplementary to ONTARGET and randomized 6,666
atients with a profile similar to that of patients in the
NTARGET study but who were intolerant of ACE
nhibition. The patients were randomly allocated to telmis-
rtan 80 mg/day versus placebo (16). The composite pri-
ary end point was identical to that in the ONTARGET
tudy (see preceding text). The median follow-up was 56
onths, mean BP at baseline was 141/82 mm Hg, and 76%
f the patients were hypertensive, the majority receiving
oncomitant treatment with other BP-lowering medica-
ions. The BP difference throughout the trial was 4.0/2.2
m Hg lower with telmisartan versus placebo. The event
ate for the primary outcome was lower with telmisartan
15.7%) than with placebo (17%), but this was not signifi-
ant. Review of the components of the primary composite
utcome showed that there were fewer myocardial infarc-
ions and strokes in the telmisartan group than in the
lacebo group, but this was not significant. There were also
onsignificant reductions in new diabetes and new left
entricular hypertrophy in the telmisartan group. Total
ortality, the number of cardiovascular deaths, and hospi-
alizations for heart failure were similar between the 2
roups. This result will come as a surprise to many because
ctive BP-lowering treatment would be expected to be more
ffective than placebo at reducing cardiovascular events.
oreover, based on usual data with BP-lowering mono-
herapy, one might have expected a greater difference in BP
etween active treatment and placebo. There are a number
f potential explanations. First, it is often the case that when
ctive BP-lowering treatment is compared with placebo,
espite the blinded nature of the trial, add-on BP-lowering
herapy is greater in the placebo group, reducing the
nticipated difference in BP between groups. This clearly
appened in the TRANSCEND trial because there was
ignificantly more additional use of ARBs, diuretics,
alcium-channel blockers (CCBs), and ARBs in the placebo
ersus telmisartan groups. That would serve to minimize the
ifference in BP between groups and hence the power of the
tudy to detect a difference in the primary outcome. This
onfounding, namely, greater add-on therapy, in the pla-
ebo arm has happened before, in the SCOPE (Study on
ognition and Prognosis in the Elderly) trial (17), when a
omparison between candesartan versus placebo in elderly
ypertensive patients also generated a null result because
here was a less than expected difference in BP between
roups. Second, BP lowering would also be expected to
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roups. This observation is most likely explained by the use
f more add-on diuretic therapy among the placebo-treated
atients. Moreover, as heart failure was the second most
ommonly occurring component of the primary outcome,
hat would have further diminished the power of the study.
hird, overall, the TRANSCEND study seems to lack
tatistical power for reasons highlighted in preceding text
ut also because of the number of patients included in the
rial and its duration. It is difficult to reconcile how a study
odeled on a patient population and design similar to the
OPE trial could have adequate statistical power with only
,926 patients compared with 9,000 patients in the HOPE
rial (10). Moreover, the TRANSCEND study patients
eceived better background treatment, for example, statins
nd antiplatelet therapy and thus experienced a lower event
ate when compared with the HOPE trial patients. Thus,
ne has to conclude that the TRANSCEND study result
ooks like a problem of statistical power. With this in mind,
he result of the ONTARGET study becomes especially
mportant and reassuring in showing noninferiority of
elmisartan in a head-to-head comparison with ramipril (9).
he PROFESS (Prevention Regimen for Effectively
voiding Second Strokes) trial and BP lowering after
troke. The PROFESS trial compared telmisartan and
lacebo in 20,332 patients who had recently suffered an
schemic stroke (18). The primary outcome was recurrent
troke. The median time from stroke to randomization was
nly 15 days, and the mean follow-up was 2.5 years. The BP
ifference between groups was once again less than antici-
ated at only 3.2/2.0 mm Hg. There was no difference in
he primary outcome, although recurrent stroke, major
ardiovascular events, and new onset of diabetes were
odestly but nonsignificantly lower among the patients
ssigned to telmisartan. This result was also surprising when
ne considers the prior evidence, for example, the
ROGRESS (Perindopril Protection Against Recurrent
troke Study) (19), showing that BP lowering is an effective
trategy to reduce the risk of recurrent stroke. So, how do
e reconcile this result? First, the baseline BP was slightly
igher and the BP lowering substantially greater (12.3/
.0 mm Hg) in the PROGRESS study. This result is
xplained in that the PROGRESS study used a combi-
ation of an ACE inhibitor/diuretic (perindopril/
ndapamide) for most patients. Indeed, among the pa-
ients in the PROGRESS study who only received
erindopril and thus experienced a lesser fall in BP
4.9/2.8 mm Hg), there was no significant reduction in
troke. The smaller than anticipated fall in BP with
elmisartan in the PROFESS trial is most likely explained
y the fact that add-on BP-lowering therapy in the placebo
roup was greater, reflecting the desire of physicians to
mprove BP control in patients after stroke. Second, the
edian time to randomization to BP-lowering therapy was
ubstantially different when comparing the PROFESS study
15 days) with the PROGRESS study (8 months), and the wurations of the studies were also different: PROFESS 2.5
ears versus PROGRESS 4.5 years. This latter point may be
rucial because the outcomes between placebo versus telmisar-
an in the PROFESS trial did appear to be diverging after2
ears in favor of telmisartan. Indeed, in previous studies such as
OPE (10) and LIFE (Losartan Intervention for Endpoint
eduction in Hypertension) (20), which ultimately showed
ignificant benefits of an ACE inhibitor or ARB, respec-
ively, on stroke rates, there was little difference in outcomes
etween treatment groups in the first 12 months, suggesting
he importance of longer follow-up. Maybe the 2.5 years of
ollow-up in the PROFESS study was simply too short to
eveal a significant difference in outcomes, especially in light
f the smaller than expected difference in BP between
roups. Finally, the PROFESS study adopted a factorial
esign that also compared different antiplatelet strategies—
here was no evidence of an interaction between these
reatment strategies with regard to the outcomes, so this is
nlikely to have influenced the outcome (18).
The somewhat surprising results of the TRANSCEND and
ROFESS studies may thus be explained by inadequate
tatistical power and study duration, respectively. A pre-
pecified combined analysis of data from the TRANSCEND
nd PROFESS studies provided more robust power to exam-
ne the effects of telmisartan versus placebo and showed a
ignificant benefit of telmisartan therapy on a primary com-
osite outcome of cardiovascular death, myocardial infarction,
nd stroke with or without heart failure (16). This finding
ends support to the aforementioned interpretation of the
RANSCEND study and PROFESS study results.
re you never too old to start treatment for hypertension?
he results of HYVET (Hypertension in the Very El-
erly Trial). International hypertension treatment guide-
ines have remained appropriately cautious with regard to
reatment recommendations for people over the age of 80
ears because of a lack of data confirming the safety and
fficacy of treatment. There were legitimate concerns that
he potential benefits of BP lowering could be offset by
arm due to complications such as hypotension-related
yncope and mortality. Indeed, a pilot study for a trial of BP
owering in the very elderly reported a reduction in stroke
isk that was offset by an increased risk of mortality with
P-lowering therapy (21). Understanding the balance of
enefit versus harm with BP lowering has been com-
ounded by the very elderly invariably having been excluded
rom recruitment into prior major clinical outcomes trials of
P-lowering therapy, and as a consequence, there was
nadequate evidence upon which to base clinical guidance.
hese important issues were addressed by the HYVET
tudy of BP-lowering treatment in the very elderly (22). The
YVET study randomized 3,845 patients from Europe,
hina, Australasia, and Tunisia who were 80 years of age or
lder (mean age 83.6 years) and had a sustained systolic BP
f 160 mm Hg or more (mean seated BP at baseline was
73.0/90.8 mm Hg). The patients received active treatment















































































































70 Williams JACC Vol. 55, No. 1, 2010
Year in Hypertension December 29, 2009/January 5, 2010:65–73aily) or matching placebo. The ACE inhibitor perindopril
2 or 4 mg), or matching placebo, was added when required
o achieve the target BP of 150/80 mm Hg. The primary
nd point was fatal or nonfatal stroke. The baseline history
f cardiovascular disease was only 11.8%, indicating that
his was a relatively healthy elderly population. Blood
ressure was reduced to 143.5/75.4 mm Hg with active
reatment and to 158.5/84 mm Hg with placebo, a differ-
nce in BP lowering of 15/8.6 mm Hg for a median
ollow-up of 1.8 years. The study was discontinued on the
ecommendation of the Data Safety Monitoring Board after
median follow-up of 1.8 years because of a significant
eduction in all-cause mortality of 21% in favor of active
reatment. This finding was unexpected, mindful of the data
rom the HYVET pilot study, which had suggested the
ossibility of an increase in mortality with BP-lowering
reatment. At the time of study cessation there had also
een a 30% reduction in the rate of fatal or nonfatal stroke,
hich just failed to reach significance, and a 39% significant
eduction in the risk of fatal stroke. There was also an
mpressive 64% reduction in the rate of heart failure, which
as highly significant. Reassuringly, fewer serious adverse
vents were reported in the active-treatment group. These
ndings are important and are likely to influence recom-
endations for the treatment of the very elderly in future
uidelines. An important caveat is that the HYVET study
opulation appeared healthier than is often the case for
eople at this age, emphasizing that doctors must always
ssess the potential of treatment with regard to the expec-
ations of benefit in the individual patient. That said, the
YVET study has provided unequivocal evidence that the
enefits of BP lowering in the very elderly can be very
ubstantial, removing justification for equivocation. As a
onsequence of this landmark finding, many more very
lderly patients will be actively treated with BP-lowering
herapy.
P-lowering therapy and cognitive function. The
YVET study also included an assessment of the impact of
P-lowering therapy on incident dementia in the very
lderly (23). There were fewer cases of dementia in the
ctively treated group but this result did not reach signifi-
ance, probably because of the very short duration of the
tudy. When the data from the HYVET study were
ombined in a meta-analysis with data from other placebo-
ontrolled studies that have assessed the impact of BP-
owering therapy on incident dementia, there was a reduc-
ion in incident dementia of marginal significance with
ctive treatment (23). Nevertheless, it should be recognized
hat clinical trials are of relatively short duration and by
ecessity use unsophisticated methods to assess cognitive
unction. If the impact of BP-lowering therapy over a
ifetime of treatment serves to better preserve cognitive
unction later in life, which I think it will, then this could
urn out to be one of the most compelling reasons for
reating hypertension in younger people. mncident heart failure in hypertension: new data from
LLHAT (Antihypertensive and Lipid-Lowering Treat-
ent to Prevent Heart Attack Trial). The HYVET study
emonstrated a very large reduction in incident heart failure
mong hypertensive very elderly patients treated with
iuretic-based therapy. A recent analysis of the ALLHAT
tudy underscores the strong influence of diuretic therapy on
ncident heart failure among high-risk hypertensive patients
24). The report examined incident hospitalized heart fail-
re in patients with preserved ejection fraction (50%) or
educed ejection fraction (50%). In the ALLHAT study,
2,418 high-risk hypertensive patients were randomly as-
igned to chlorthalidone, amlodipine, lisinopril, or doxazo-
in. In a pre-specified substudy, ejection fraction was esti-
ated by contrast ventriculography, echocardiography, or
adionuclide study in 910 of 1,367 patients (66.6%) with
ospitalized heart failure events meeting ALLHAT study
riteria. Chlorthalidone significantly reduced the risk of
eart failure with preserved ejection fraction as compared
ith amlodipine (31%), lisinopril (26%), or doxazosin
47%). Chlorthalidone also significantly reduced the risk
f heart failure with reduced ejection fraction when com-
ared with amlodipine (26%) or doxazosin (39%). The
isk of heart failure with reduced ejection fraction was
imilar with chlorthalidone and lisinopril. The report also
rovided a stark reminder that the development of heart
ailure in hypertensive patients has serious consequences.
nce heart failure had occurred in the ALLHAT study,
eath was more common among patients with reduced
jection fraction (42%) when compared with patients who
ad preserved ejection fraction (29%). These data under-
core the importance of early and optimal intervention to
ontrol BP to prevent the onset of heart failure and the
ffectiveness of diuretic-based therapy in achieving this
bjective.
ombination therapy for hypertension: mission accom-
lished? Continuing the theme of trials that are likely to
nfluence clinical practice, the ACCOMPLISH (Avoid-
ng Cardiovascular Events Through Combination Ther-
py in Patients Living With Systolic Hypertension) trial
eported its principal findings in 2008 (25). We know
hat combinations of BP-lowering drugs are required to
chieve optimal BP control for most patients. Despite
his, the majority of trials of BP-lowering therapy have
ocused on initial treatment with monotherapy, and there
as been too little emphasis on the potential importance of
he composition of subsequent combinations of therapies.
he ACCOMPLISH trial specifically evaluated whether
he type of combination therapy is important in influencing
linical outcomes by comparing 2 different single-pill com-
inations, namely, an ACE inhibitor (benazepril) plus a
iuretic (hydrochlorthiazide), versus the same ACE inhib-
tor combined with a CCB (amlodipine). This randomized,
ouble-blind trial included 11,506 high-risk hypertensive
atients with a mean age of 68 years; 60% had diabetes, and
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December 29, 2009/January 5, 2010:65–73 Year in Hypertensionyocardial infarction and 36% with previous coronary
evascularization), 13% had prior stroke, and a similar
ercentage had electrocardiographically documented left
entricular hypertrophy. Furthermore, before randomiza-
ion, most patients (97%) were already being treated for
ypertension, with 75% receiving 2 or more classes of
ntihypertensive medications. Despite this, only 37.3% had
BP140/90 mm Hg at baseline, indicating that as well as
eing high risk, they were also most likely a group with
uite severe hypertension. The primary outcome of the
CCOMPLISH trial was a composite of death from
ardiovascular causes, nonfatal myocardial infarction, non-
atal stroke, hospitalization for angina, resuscitation after
udden cardiac arrest, and coronary revascularization. Dur-
ng the trial, achieved BP values were impressive (132/74
m Hg), differed little (1/1 mm Hg at trough) between
reatment groups, and 75% achieved the BP goal of
140/90 mm Hg. The trial was terminated early after a
ean follow-up of 36 months, when the boundary of the
re-specified stopping rule was crossed. There was a signif-
cant 20% reduction in the primary end point in favor of
he benazepril-amlodipine treated group, and all compo-
ents showed this trend. This difference does not appear to
e due to differences in BP control between groups, a
onclusion likely to be supported by data from an ambula-
ory BP monitoring substudy. Whatever the explanation for
he difference in primary outcomes between treatment
roups, the ACCOMPLISH study has established that
ombining a CCB with ACE inhibition, or presumably
ther forms of RAS blockade, is a very effective treatment
ption for high-risk patients with hypertension.
So, how do we interpret the data from the ACCOMPLISH
rial alongside that from other trials? Well, no doubt some will
uggest the era of the diuretic is waning and that a CCB should
ow be the preferred component of any combination, and
erhaps for this specific population it should. But I would urge
aution about generalization of data from a single trial. As
mpressive as the data are, 1 trial should not dictate a treatment
uideline. What we need is some balance and pragmatism.
here is no single optimal treatment for everybody with
ypertension, and once we reach a requirement for 2-drug
ombinations, physicians need choices. Most physicians would
hoose some form of RAS blockade as part of their pre-
erred treatment strategy for hypertension. The data from the
CCOMPLISH trial, alongside a wealth of data with diuret-
cs, now provides 2 excellent options to combine with RAS
lockade, namely, a diuretic or a CCB, or perhaps both for
atients with more resistant hypertension.
ingle-pill combination therapy as initial therapy for
ypertension? The data from the ACCOMPLISH study
lso showed that when patients were transferred to either of
he single-pill combinations tested in that study, there was
dramatic improvement in BP control, with 70% achiev-
ng their BP target (25). The reasons for this are not
mmediately obvious but may in part relate to improved
oncordance with therapy in a clinical trial setting. It does tend some support to current guideline recommendations of
nitial therapy with a low-dose, single-pill combination for
atients whose BP is 20/10 mm Hg above their target BP
26,27). In my view, the preferred combination based on
urrent evidence would include RAS blockade and either a
CB or a diuretic. The likelihood of this approach produc-
ng greater BP lowering than monotherapy alone seems
bvious. The main concern has been safety and tolerability
ith regard to potentially large initial BP declines in
reatment-naïve patients. The ACCOMPLISH trial can-
ot address the latter because almost all patients were
lready treated for their hypertension immediately before
andomization.
esistant hypertension. Resistant hypertension is defined
s BP that remains above goal despite the concurrent use of
antihypertensive agents of different classes. Ideally, 1 of
he 3 agents should be a diuretic, and all agents should be
rescribed at optimal dose amounts (28). This practice is
ore common for older patients and for obese patients. It is
lso more common for patients with diabetes, chronic
idney disease, and target organ damage, namely, high-risk
opulations for whom the benefits of optimizing BP control
ould be greatest. A recent scientific statement from the
merican Heart Association discusses the evaluation and
reatment of resistant hypertension (28). Of interest, a
ecent paper in the Journal reported that a common patho-
enetic factor contributing to treatment resistance in hyper-
ensive patients is large artery stiffening (29). In that study,
he cohort with the highest carotid-femoral pulse wave
elocity at baseline (indicative of arterial stiffening) was the
east likely to have their BP controlled. This observation
uggests that the many factors associated with the develop-
ent of resistant hypertension might exert their effects
hrough accelerated aging and stiffening of large conduit
rteries, putting the aorta and its functional characteristics at
he heart of resistant hypertension (30). That would also
xplain why most resistant hypertension is due to poorly
ontrolled systolic rather than diastolic BP (31).
With regard to treatment of resistant hypertension, the
vidence base is thin, and this could be a fruitful avenue for
herapeutic development, especially as the numbers of pa-
ients affected will continue to rise as populations age. This
nterest is reflected by the various classes of BP-lowering
rugs in various phases of development that may emerge as
otential therapies for patients with resistant hypertension.
hese drugs include selective endothelin receptor antago-
ists, aldosterone synthase inhibitors, longer-acting formu-
ations of clonidine, and novel diuretic agents.
A novel approach to treating patients with resistant
ypertension using radiofrequency ablation (RFA) of renal
ympathetic nerves was recently reported (32). The rationale
or this approach is that renal sympathetic tone plays a role
n the pathogenesis of resistant hypertension. The RFA was
sed to destroy renal sympathetic innervation to the kidney
hrough a percutaneous catheter in the renal artery. This
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here was 1 intraprocedural renal artery dissection, but no
ther renovascular complications. The RFA was associated
ith impressive systolic and diastolic BP reductions of 20
m Hg and 10 mm Hg, respectively, which were sustained
or as long as 12 months of observation. These BP reduc-
ions are similar to those observed in the therapeutic studies
f resistant hypertension reviewed last year (3). These initial
tudies of RFA of the renal nerves seem to justify this novel
pproach to treatment, but further large-scale studies are
equired to determine the place of this approach in more
outine clinical practice.
reatment Strategies and
essons for Guidelines: Simplicity Wins!
concerning aspect of modern guideline development is
heir increasing complexity. This contrasts with my own
uiding principle, which is, if clinical guidance cannot be
ummarized on a single page, it probably will not work. Of
ourse, the analysis and explanation of how the single page
as derived should be detailed, but the treatment algorithm
hould be simple. The BHS/NICE (British Hypertension
ociety/National Institute for Clinical Excellence) guidance
or hypertension treatment in the United Kingdom exem-
lified this with its simple A/CD algorithm, which not only
dopted a traditional step-wise approach but also specified
he classes of treatment and preferred combinations to be
sed (33). In this regard, the recent report of a similar
imple treatment algorithm tested in Canada was of interest
34). This study cluster randomly designated 45 general
ractices to use a simplified hypertension treatment algo-
ithm or the current Canadian hypertension education
rogram guidelines. The primary outcome was the propor-
ion of patients achieving their target BP after 6 months.
he simplified treatment algorithm was similar to the
HS/NICE guidelines in that it focused on the use of RAS
lockade, namely, ACE inhibition or ARB in combination
ith a diuretic or a CCB. There was, however, an important
ifference in the Canadian study approach in that all
atients began treatment with low-dose combination ther-
py, using an ACE inhibitor or ARB with a diuretic,
p-titrating the combination therapy to the highest dose at
tep 2. Addition of a CCB was recommended at the next
tep. The proportion of patients achieving the target was
ignificantly higher with the simplified guideline (64.7% vs.
2.7%). This finding sends out an important message to
uideline developers: simplicity and pragmatism win in the
eal world of hypertension treatment. With that, here ends
remarkable year in hypertension research.
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